查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2012624

脑肿瘤治疗市场：2026-2032年全球市场预测（按产品类型、治疗方法、肿瘤类型、通路和最终用户划分）

Brain Tumor Therapeutics Market by Product Type, Therapeutic Approach, Tumor Type, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，脑肿瘤治疗市场价值将达到 35.6 亿美元，到 2026 年将成长至 38.7 亿美元，到 2032 年将达到 69.9 亿美元，复合年增长率为 10.10%。

主要市场统计数据
基准年 2025 35.6亿美元
预计年份：2026年 38.7亿美元
预测年份 2032 69.9亿美元
复合年增长率 (%) 10.10%

对于决策者而言，我们整合临床创新、护理路径和商业化的优势，以建构现代化的脑肿瘤治疗格局。

脑肿瘤治疗处于快速科学创新与持续临床复杂性交彙的阶段，需要一种整合技术、临床实践和商业策略的整体商业观点。分子诊断和精准医疗的最新进展正在改变患者的治疗路径，拓宽可用的治疗方法范围，同时也提升了多学科协作的重要性。同时，影像学和外科技术的创新正在改变手术全期决策，并为医疗设备和服务供应商创造新的机会，使其能够创造可衡量的价值。

精准诊断、适应性证据产生和价值驱动型护理模式如何重塑治疗方法的开发和商业性化应用。

脑肿瘤治疗领域正经历着变革性的转变，这些转变正在重新定义临床决策和商业性优先事项。精准肿瘤学的进步，例如分子分型和标靶免疫疗法，正在将异质性疾病类别转化为更具实用性的治疗群体，从而影响临床试验设计、监管策略和市场准入顺序。除了药物研发的进步之外，影像和放射技术也在不断发展，提高了诊断的准确性并减少了继发性损伤，这迫使临床团队重新评估治疗顺序和联合治疗策略。

本研究评估了近期关税趋势如何改变了治疗药物和医疗设备。

贸易政策和关税趋势会对所有治疗领域的製造商和经销商的原材料成本和供应链产生重大影响。 2025年，美国关税的变化将对进口医疗设备和某些医药原料产生累积影响，迫使製造商重新评估其筹资策略和成本结构。对于医疗设备製造商而言，依赖全球化供应链的组件，例如成像感测器和放射治疗系统零件，正面临原材料成本飙升的困境，这导致他们不得不重新评估与医院系统和经销商商的采购谈判。

本分析检视了医疗设备和药品的需求因素以及临床路径，以确定不同的引进模式和关键的商业化策略。

关键的市场区隔洞察揭示了临床需求和商业性机会在产品类型、治疗方法、肿瘤类型、终端用户和分销管道等方面的交汇点。依产品类型分析，市场分为医疗设备和药品两大类，其中医疗设备又包括影像设备、放射治疗设备和手术器材。这种细分突显了不同引进週期、资本投资情况以及医疗服务提供者的服务模式需求。治疗方法进一步细分了市场需求，涵盖化疗、免疫疗法、放射线治疗和外科手术。化疗包括烷化剂、抗代谢药物和植物生物碱；免疫疗法包括CAR-T疗法、查核点抑制剂和疫苗；放射线治疗包括近距离放射、体外放射治疗和立体定位放射放射线手术。另一方面，外科手术方法涵盖从开颅手术到立体定位手术，每种方法都有其独特的临床工作流程和实证医学需求。

此流程旨在明确区域法规和支付方多样性，并优化证据生成、市场进入顺序和区域商业化策略，以实现全球扩张。

区域趋势决定了监管、报销和临床导入环境的差异，因此需要製定本地化的打入市场策略。在美洲，先进的学术机构和综合医疗保健系统往往推动高成本疗法和复杂医疗设备的早期应用，而私人保险公司和打包支付模式则影响着医疗服务的取得和报销途径。在欧洲、中东和非洲，监管的多样性和报销标准的差异，以及集中核准系统和分散式医疗技术评估并存的现状，使得灵活的循证数据和区域性经济模式成为必要。亚太地区的医疗现代化过程呈现多样化的发展路径。在一些市场，医院的快速扩张和对肿瘤中心的投资催生了对高性能医疗设备和新型疗法的巨大需求，而在其他市场，成本控制和本地化生产伙伴关係至关重要。

创新者、医疗设备製造商和经销商如何透过整合产品和服务策略来重新定义竞争优势和伙伴关係模式。

脑肿瘤治疗生态系统中的主要企业在互补领域开展业务，包括创新药物研发商、医疗设备製造商、服务供应商和专业经销商，他们各自为复杂的价值链做出贡献。製药创新者正日益将分子标靶药物和免疫疗法与伴随诊断相结合，而基于生物标记的患者选择在临床和商业性成功中发挥越来越重要的作用。医疗设备製造商则透过整合成像、导航和药物输送的整合解决方案来脱颖而出，从而简化手术流程并改善临床疗效。

为了加快招募速度，经营团队优先考虑整合证据产生、供应弹性和灵活的商业化。

产业领导者应优先考虑一系列切实可行的倡议，使科学差异化与现实的商业性可行性和支付方的预期相契合。首先，投资于有针对性的证据生成，将临床终点与卫生经济效益连结起来，使支付者和医疗保健系统不仅能够评估短期疗效，还能评估长期价值。其次，透过采购多元化、确保关键零件的冗余以及将关税和贸易敏感性分析纳入定价模式，优化供应链韧性，以保障获利能力和医疗保健服务的连续性。第三，开发能够反映终端用户多样性的灵活商业模式。医院、门诊手术中心和专科诊所各自需要不同的部署、资金筹措和服务合约。

我们结合临床、商业和政策知识，采用透明的混合方法（包括专家访谈和比较案例分析），确保提供可操作的见解。

本分析的调查方法结合了系统性的文献综述、对各领域专家的定性检验以及对二手资料来源的三角验证，以确保研究结果的稳健性和有效性。访谈对象包括临床医生、医院采购经理、医疗设备工程师、保险公司和商业部门主管，旨在收集不同领域对临床效用、采购偏好和市场进入风险的观点。二级资讯来源，包括同行评审的临床文献、监管文件、指南更新和公共公告，均基于检验的证据和当前的实践模式，为研究结果提供了支持。

找到能够整合临床创新、商业性严谨性和区域差异的策略槓桿，将治疗进步转化为持久影响。

总之，脑肿瘤治疗领域的特点是科学进步日新月异、诊疗路径不断演变以及商业性环境复杂多变，所有这些因素共同要求在实证医学、供应链设计和市场进入方面采取整合策略。精准诊断和新型免疫疗法提高了临床鑑别诊断的标准，而影像学、放射疗法和外科手术技术的进步正在重塑治疗模式。同时，关税和贸易的波动暴露了供应链的脆弱性，需要积极主动的管理来维持医疗资源的可近性和财务绩效。监管和报销机制的区域差异进一步凸显了製定区域性策略和伙伴关係关係的必要性。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：脑肿瘤治疗市场：依产品类型划分

  • 医疗设备
    • 医疗影像设备
    • 放射治疗设备
    • 手术器械
  • 製药

第九章：脑肿瘤药物市场（依治疗方法划分）

  • 化疗
    • 烷化剂
    • 抗代谢物
    • 植物生物碱
  • 免疫疗法
    • CAR T
    • 查核点抑制剂
    • 疫苗
  • 放射线治疗
    • 近距离放射治疗
    • 远端辐射
    • 立体定位放射放射线手术
  • 外科手术
    • 开颅手术
    • 立体定位手术

第十章：依肿瘤类型分類的脑肿瘤治疗市场

  • 星状细胞瘤
  • 胶质母细胞瘤
  • 脑膜瘤

第十一章：脑肿瘤治疗市场：依通路划分

  • 医院药房
  • 网路药房
  • 零售药房

第十二章：脑肿瘤治疗市场：依最终用户划分

  • 门诊手术中心
  • 医院
  • 专科诊所

第十三章：脑肿瘤治疗市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章：脑肿瘤治疗市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 脑肿瘤治疗市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国脑肿瘤治疗市场

第十七章：中国脑肿瘤治疗市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca plc
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Celldex Therapeutics, Inc.
  • CNS Pharmaceuticals, Inc.
  • Daiichi Sankyo Co., Ltd.
  • Eisai Co., Ltd.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc
  • Kintara Therapeutics, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Novocure Ltd.
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.
Product Code: MRR-4342CA326550

The Brain Tumor Therapeutics Market was valued at USD 3.56 billion in 2025 and is projected to grow to USD 3.87 billion in 2026, with a CAGR of 10.10%, reaching USD 6.99 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 3.56 billion
Estimated Year [2026] USD 3.87 billion
Forecast Year [2032] USD 6.99 billion
CAGR (%) 10.10%

Framing the contemporary brain tumor therapeutic environment by integrating clinical innovation, care pathways, and commercialization levers for decision-makers

Brain tumor therapeutics sit at the intersection of rapid scientific innovation and enduring clinical complexity, requiring an executive lens that integrates technology, clinical practice, and commercial strategy. Recent advances in molecular diagnostics and precision therapeutics have altered patient pathways, expanding the range of interventions available while also increasing the importance of coordinated care across multidisciplinary teams. At the same time, procedural innovations in imaging and surgical techniques have changed perioperative decision making, creating new opportunities for device and service providers to add demonstrable value.

This introduction positions the report as a focused synthesis of clinical, regulatory, and commercial dynamics shaping therapeutic choices for primary brain tumors. It outlines the prevailing therapeutic approaches, the role of complementary devices, and how end users such as hospitals, specialty clinics, and ambulatory surgical centers are adapting care pathways. Throughout, emphasis is placed on evidence-based adoption drivers, reimbursement and access considerations, and the strategic implications for companies developing devices or pharmacologic therapies. The aim is to equip decision-makers with a concise framing of the problem set, the levers that matter in commercialization, and the domains where additional investment or collaboration can yield measurable clinical and economic returns.

How precision diagnostics, adaptive evidence generation, and value-focused care models are reshaping therapeutic development and commercial execution

The landscape for brain tumor therapeutics is undergoing transformative shifts that are redefining clinical decision-making and commercial priorities. Precision oncology advances, such as molecular subtyping and targeted immunotherapies, have converted heterogeneous disease categories into more actionable treatment cohorts, thereby influencing trial design, regulatory strategy, and market entry sequencing. Parallel to pharmacologic progress, imaging and radiation technologies have evolved to provide greater precision and reduced collateral damage, prompting clinical teams to reassess treatment sequencing and combination strategies.

Concurrently, the convergence of digital health, real-world evidence, and adaptive clinical trial frameworks has accelerated iterative learning, shortening the time between proof-of-concept and broader clinical adoption. Payers and health systems are increasingly focused on value-based metrics, pushing manufacturers to demonstrate not only efficacy but also longitudinal patient outcomes and cost-effectiveness. As a result, organizations that can align scientific differentiation with pragmatic deployment pathways-such as optimized distribution channels and hospital integration models-will capture disproportionate clinical and commercial upside. These shifts compel manufacturers and providers to rethink partnerships, evidence generation, and market access pathways in order to remain competitive.

Assessing how recent tariff developments have altered supply chain resilience, procurement dynamics, and commercial cost structures in therapeutics and devices

Trade policy and tariff dynamics can introduce material cost and supply chain considerations for manufacturers and distributors across therapeutic modalities. In 2025, tariff changes in the United States have had a cumulative effect on imported devices and certain pharmaceutical inputs, prompting manufacturers to reassess sourcing strategies and cost structures. For device makers, components that rely on globalized supply chains, including imaging sensors or radiation delivery system parts, experienced input-cost inflation that translated to revised procurement discussions with hospital systems and distributors.

Pharmaceutical manufacturers faced indirect cost pressure where APIs and specialty packaging were sourced internationally, requiring contract renegotiations and, in some instances, partial reshoring or diversification of suppliers. These adjustments increase the importance of supply chain transparency and contractual flexibility with end users. Providers and payers responded by seeking stronger total-cost-of-care evidence and longer-term warranties or service commitments to mitigate variability. Moving forward, stakeholders that proactively model tariff-related expenses into pricing, managed procurement, and clinical value propositions will be better positioned to sustain margins while preserving access and adoption.

Dissecting demand drivers across devices versus pharmaceuticals and clinical pathways to reveal differentiated adoption patterns and commercialization levers

Key segmentation insights reveal where clinical demand and commercial opportunity intersect across product type, therapeutic approach, tumor type, end user, and distribution channels. When analyzed by product type, the market divides into devices and pharmaceutical offerings, with devices themselves comprising imaging equipment, radiation equipment, and surgical instruments; this division highlights different adoption cycles, capital expenditure profiles, and service model requirements for providers. Therapeutic approach further stratifies demand across chemotherapy, immunotherapy, radiotherapy, and surgery; chemotherapy includes alkylating agents, antimetabolites, and plant alkaloids, while immunotherapy encompasses CAR T therapies, checkpoint inhibitors, and vaccines, and radiotherapy spans brachytherapy, external beam radiotherapy, and stereotactic radiosurgery, whereas surgical approaches range from craniotomy to stereotactic surgery, each pathway implicating distinct clinical workflows and evidence needs.

Tumor type segmentation-astrocytoma, glioblastoma, and meningioma-illustrates heterogeneous clinical outcomes and treatment intensity, which in turn affect product selection and service utilization. End users such as ambulatory surgical centers, hospitals, and specialty clinics differ in their capital budgets, case-mix, and referral networks, shaping procurement timelines and commercial engagement strategies. Distribution channels including hospital pharmacies, online pharmacies, and retail pharmacies influence patient access, adherence support, and channel economics. Taken together, these segmentations underline that tailoring clinical evidence, pricing models, and post-market services to the specific combination of product, therapy, tumor type, and care setting is essential to accelerate adoption and create defensible commercial positioning.

Unpacking regional regulatory and payer heterogeneity to tailor evidence generation, market entry sequencing, and local commercialization tactics for global reach

Regional dynamics create distinct regulatory, reimbursement, and clinical adoption environments that require localized go-to-market strategies. In the Americas, advanced academic centers and integrated health systems often drive early adoption of high-cost therapeutics and complex devices, while private payers and bundled payment models shape access and reimbursement pathways. Europe, the Middle East & Africa encompasses regulatory heterogeneity and varying reimbursement thresholds, where centralized approvals coexist with decentralized health technology assessments, necessitating flexible evidence dossiers and region-specific economic models. Asia-Pacific presents diverse healthcare modernization trajectories; in some markets rapid hospital expansion and investment in oncology centers create significant demand for high-capability devices and novel therapeutics, whereas other markets emphasize cost containment and local manufacturing partnerships.

These regional contrasts affect clinical trial site selection, timing of market entry, and the design of patient access programs. Manufacturers must therefore calibrate regulatory strategies, local evidence generation, and distribution partnerships to align with regional payer expectations and provider capabilities. Moreover, engagement with key opinion leaders and local clinical networks is essential to translate global evidence into locally relevant practice change and to expedite reimbursement discussions in each jurisdiction.

How integrated product and service strategies among innovators, device makers, and distributors are redefining competitive advantage and partnership models

Key companies in the brain tumor therapeutics ecosystem operate across complementary domains-innovative drug developers, device manufacturers, service providers, and specialized distributors-each contributing to a complex value chain. Pharmaceutical innovators are increasingly pairing molecularly targeted agents and immunotherapies with companion diagnostics, elevating the role of biomarker-driven patient selection in clinical and commercial success. Device manufacturers are differentiating through integrated solutions that combine imaging, navigation, and therapeutic delivery to streamline operative workflows and improve clinical outcomes.

Service providers and contract research organizations are expanding offerings to support adaptive trial designs, real-world evidence platforms, and health economic modeling, enabling sponsors to substantiate value propositions more rapidly. Distributors and specialty pharmacies are enhancing patient support programs and specialty logistics to address the needs of high-acuity populations. Across the ecosystem, strategic collaborations-whether co-development, licensing, or integrated service agreements-have become a preferred vehicle to de-risk innovation and accelerate time-to-clinic or time-to-market. Organizations that can demonstrate integrated solutions, scalable support models, and strong clinical evidence will lead in both clinical adoption and long-term commercial sustainability.

Prioritized strategic moves for executives to synchronize evidence generation, supply resilience, and flexible commercialization to accelerate adoption

Industry leaders should prioritize a set of actionable initiatives that align scientific differentiation with pragmatic commercial execution and payer expectations. First, invest in targeted evidence generation that pairs clinical endpoints with health economic outcomes, enabling payers and health systems to assess long-term value alongside short-term efficacy. Second, optimize supply chain resilience by diversifying sourcing, building redundancy for critical components, and embedding tariff and trade sensitivity analyses into pricing models to protect margins and continuity of care. Third, develop flexible commercial models that reflect end-user variability; hospitals, ambulatory surgical centers, and specialty clinics require different acquisition, financing, and service arrangements.

Additionally, engage early with regional regulatory and reimbursement stakeholders to ensure local evidence requirements are met, and consider adaptive trial designs or pragmatic studies to accelerate real-world adoption. Form strategic alliances that integrate devices and therapeutics with digital tools and patient support services to create bundled value propositions. Finally, prioritize clinician and patient education programs that clarify treatment sequencing, combination therapy rationale, and outcome expectations, thereby smoothing the pathway from regulatory approval to standard-of-care integration. Collectively, these actions will reduce barriers to adoption and enhance commercial resilience.

A transparent mixed-methods approach combining clinical, commercial, and policy intelligence with expert interviews and comparative case analyses to ensure actionable insights

The research methodology underpinning this analysis combines systematic literature review, primary qualitative interviews with subject matter experts, and triangulation of secondary data sources to ensure robustness and relevance. Primary interviews included clinicians, hospital procurement leaders, device engineers, payers, and commercial executives to capture cross-functional perspectives on clinical utility, procurement preferences, and market access contingencies. Secondary sources encompassed peer-reviewed clinical literature, regulatory filings, guideline updates, and public policy announcements to ground the findings in verifiable evidence and current practice patterns.

Data synthesis employed thematic analysis to identify recurring adoption drivers, barriers, and regional variances, while comparative case studies highlighted successful commercialization and partnership archetypes. Where appropriate, sensitivity checks were performed to validate assumptions around supply chain dynamics and provider purchasing behaviors. The methodology emphasizes transparency in source attribution and analytical assumptions and was designed to produce actionable insights that are reliable for strategic planning, partnership evaluation, and evidence generation prioritization.

Synthesizing clinical innovation, commercial rigor, and regional nuance to identify the strategic levers that convert therapeutic advances into durable impact

In conclusion, the brain tumor therapeutics arena is characterized by rapid scientific progress, evolving care pathways, and complex commercial dynamics that together demand integrated strategies across evidence generation, supply chain design, and market access. Precision diagnostics and novel immunotherapies have raised the bar for clinical differentiation, while advances in imaging, radiation delivery, and surgical technique are reshaping practice patterns. At the same time, tariff and trade shifts have exposed supply chain vulnerabilities that require proactive management to preserve access and fiscal performance. Regional heterogeneity in regulation and reimbursement further underscores the need for localized strategies and partnerships.

Taken together, organizations that can align robust clinical evidence with pragmatic commercial models, resilient procurement practices, and targeted regional engagement will be best positioned to convert innovation into sustained clinical and commercial impact. The path forward emphasizes collaboration across industry, clinical, and payer stakeholders, and a disciplined approach to evidence and value demonstration that meets the needs of providers and patients alike.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Brain Tumor Therapeutics Market, by Product Type

  • 8.1. Devices
    • 8.1.1. Imaging Equipment
    • 8.1.2. Radiation Equipment
    • 8.1.3. Surgical Instruments
  • 8.2. Pharmaceutical

9. Brain Tumor Therapeutics Market, by Therapeutic Approach

  • 9.1. Chemotherapy
    • 9.1.1. Alkylating Agents
    • 9.1.2. Antimetabolites
    • 9.1.3. Plant Alkaloids
  • 9.2. Immunotherapy
    • 9.2.1. CAR T
    • 9.2.2. Checkpoint Inhibitors
    • 9.2.3. Vaccines
  • 9.3. Radiotherapy
    • 9.3.1. Brachytherapy
    • 9.3.2. External Beam Radiotherapy
    • 9.3.3. Stereotactic Radiosurgery
  • 9.4. Surgery
    • 9.4.1. Craniotomy
    • 9.4.2. Stereotactic Surgery

10. Brain Tumor Therapeutics Market, by Tumor Type

  • 10.1. Astrocytoma
  • 10.2. Glioblastoma
  • 10.3. Meningioma

11. Brain Tumor Therapeutics Market, by Distribution Channel

  • 11.1. Hospital Pharmacies
  • 11.2. Online Pharmacies
  • 11.3. Retail Pharmacies

12. Brain Tumor Therapeutics Market, by End User

  • 12.1. Ambulatory Surgical Centers
  • 12.2. Hospitals
  • 12.3. Specialty Clinics

13. Brain Tumor Therapeutics Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Brain Tumor Therapeutics Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Brain Tumor Therapeutics Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Brain Tumor Therapeutics Market

17. China Brain Tumor Therapeutics Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. AbbVie Inc.
  • 18.6. Amgen Inc.
  • 18.7. AstraZeneca plc
  • 18.8. Bayer AG
  • 18.9. Bristol-Myers Squibb Company
  • 18.10. Celldex Therapeutics, Inc.
  • 18.11. CNS Pharmaceuticals, Inc.
  • 18.12. Daiichi Sankyo Co., Ltd.
  • 18.13. Eisai Co., Ltd.
  • 18.14. F. Hoffmann-La Roche Ltd.
  • 18.15. GlaxoSmithKline plc
  • 18.16. Kintara Therapeutics, Inc.
  • 18.17. Merck & Co., Inc.
  • 18.18. Novartis AG
  • 18.19. Novocure Ltd.
  • 18.20. Pfizer Inc.
  • 18.21. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TUMOR TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES BRAIN TUMOR THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA BRAIN TUMOR THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY IMAGING EQUIPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY IMAGING EQUIPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY IMAGING EQUIPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY RADIATION EQUIPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY RADIATION EQUIPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY RADIATION EQUIPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SURGICAL INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SURGICAL INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SURGICAL INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PHARMACEUTICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PHARMACEUTICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PHARMACEUTICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY ALKYLATING AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY ALKYLATING AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY ALKYLATING AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY ANTIMETABOLITES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY ANTIMETABOLITES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY ANTIMETABOLITES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PLANT ALKALOIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PLANT ALKALOIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PLANT ALKALOIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CAR T, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CAR T, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CAR T, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY RADIOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY RADIOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY RADIOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY RADIOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY BRACHYTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY BRACHYTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY BRACHYTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY EXTERNAL BEAM RADIOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY EXTERNAL BEAM RADIOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY EXTERNAL BEAM RADIOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY STEREOTACTIC RADIOSURGERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY STEREOTACTIC RADIOSURGERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY STEREOTACTIC RADIOSURGERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SURGERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SURGERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SURGERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CRANIOTOMY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CRANIOTOMY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CRANIOTOMY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY STEREOTACTIC SURGERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY STEREOTACTIC SURGERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY STEREOTACTIC SURGERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY ASTROCYTOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY ASTROCYTOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY ASTROCYTOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY GLIOBLASTOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY GLIOBLASTOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY GLIOBLASTOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY MENINGIOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY MENINGIOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY MENINGIOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. AMERICAS BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 101. AMERICAS BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 102. AMERICAS BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 103. AMERICAS BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2032 (USD MILLION)
  • TABLE 104. AMERICAS BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 105. AMERICAS BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 106. AMERICAS BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY RADIOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 107. AMERICAS BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 108. AMERICAS BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. AMERICAS BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 110. AMERICAS BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 116. NORTH AMERICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY RADIOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. LATIN AMERICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY RADIOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 130. LATIN AMERICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 132. LATIN AMERICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY RADIOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY RADIOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 155. MIDDLE EAST BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. MIDDLE EAST BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. MIDDLE EAST BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 158. MIDDLE EAST BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2032 (USD MILLION)
  • TABLE 159. MIDDLE EAST BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 160. MIDDLE EAST BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 161. MIDDLE EAST BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY RADIOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 162. MIDDLE EAST BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 163. MIDDLE EAST BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. MIDDLE EAST BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 165. MIDDLE EAST BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 166. AFRICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 167. AFRICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. AFRICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 169. AFRICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2032 (USD MILLION)
  • TABLE 170. AFRICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 171. AFRICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 172. AFRICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY RADIOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 173. AFRICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 174. AFRICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. AFRICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 176. AFRICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 177. ASIA-PACIFIC BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 178. ASIA-PACIFIC BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 179. ASIA-PACIFIC BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 180. ASIA-PACIFIC BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2032 (USD MILLION)
  • TABLE 181. ASIA-PACIFIC BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 182. ASIA-PACIFIC BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 183. ASIA-PACIFIC BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY RADIOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 184. ASIA-PACIFIC BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 185. ASIA-PACIFIC BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 186. ASIA-PACIFIC BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 187. ASIA-PACIFIC BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 188. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 189. ASEAN BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. ASEAN BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. ASEAN BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 192. ASEAN BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2032 (USD MILLION)
  • TABLE 193. ASEAN BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 194. ASEAN BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 195. ASEAN BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY RADIOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 196. ASEAN BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 197. ASEAN BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 198. ASEAN BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 199. ASEAN BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 200. GCC BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 201. GCC BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 202. GCC BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 203. GCC BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2032 (USD MILLION)
  • TABLE 204. GCC BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 205. GCC BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 206. GCC BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY RADIOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 207. GCC BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 208. GCC BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 209. GCC BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 210. GCC BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPEAN UNION BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPEAN UNION BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPEAN UNION BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPEAN UNION BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPEAN UNION BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 216. EUROPEAN UNION BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPEAN UNION BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY RADIOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPEAN UNION BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPEAN UNION BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPEAN UNION BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPEAN UNION BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 222. BRICS BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 223. BRICS BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 224. BRICS BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 225. BRICS BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2032 (USD MILLION)
  • TABLE 226. BRICS BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 227. BRICS BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 228. BRICS BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY RADIOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 229. BRICS BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 230. BRICS BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 231. BRICS BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 232. BRICS BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 233. G7 BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 234. G7 BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 235. G7 BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 236. G7 BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2032 (USD MILLION)
  • TABLE 237. G7 BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 238. G7 BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 239. G7 BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY RADIOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 240. G7 BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 241. G7 BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 242. G7 BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 243. G7 BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 244. NATO BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 245. NATO BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 246. NATO BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 247. NATO BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2032 (USD MILLION)
  • TABLE 248. NATO BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 249. NATO BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 250. NATO BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY RADIOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 251. NATO BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 252. NATO BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 253. NATO BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 254. NATO BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 255. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 256. UNITED STATES BRAIN TUMOR THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 257. UNITED STATES BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 258. UNITED STATES BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 259. UNITED STATES BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2032 (USD MILLION)
  • TABLE 260. UNITED STATES BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 261. UNITED STATES BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 262. UNITED STATES BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY RADIOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 263. UNITED STATES BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 264. UNITED STATES BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 265. UNITED STATES BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 266. UNITED STATES BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 267. CHINA BRAIN TUMOR THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 268. CHINA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 269. CHINA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 270. CHINA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2032 (USD MILLION)
  • TABLE 271. CHINA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 272. CHINA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 273. CHINA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY RADIOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 274. CHINA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 275. CHINA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 276. CHINA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 277. CHINA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)